Celldex Therapeutics, Inc.

General ticker "CLDX" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $1.8B

Celldex Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -24.8%.

Estimated limits based on current volatility of 2.9%: low 24.30$, high 25.76$

Factors to consider:

  • Price in estimated range
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [23.80$, 52.32$]
  • 2024-12-30 to 2025-12-30 estimated range: [17.43$, 40.60$]

Financial Metrics affecting the CLDX estimates:

  • Negative: Non-GAAP EPS, $ of -2.65 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -6.16 <= 2.35
  • Negative: negative Net income
  • Positive: Interest expense per share, $ of 0 <= 0
  • Positive: -3.48 < Investing cash flow per share, $ of -2.18

Similar symbols

Short-term CLDX quotes

Long-term CLDX plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $6.06MM $0.00MM $0.00MM
Operating Expenses $77.30MM $115.23MM $154.54MM
Operating Income $-71.24MM $-115.23MM $-154.54MM
Non-Operating Income $0.51MM $2.91MM $13.11MM
R&D Expense $53.31MM $82.26MM $118.01MM
Income(Loss) $-70.74MM $-112.33MM $-141.43MM
Taxes $-0.23MM $0.00MM $0.00MM
Profit(Loss) $-70.51MM $-112.33MM $-141.43MM
Stockholders Equity $419.48MM $326.20MM $429.17MM
Assets $444.65MM $352.74MM $465.63MM
Operating Cash Flow $-60.91MM $-103.73MM $-107.29MM
Capital expenditure $1.25MM $1.83MM $1.82MM
Investing Cash Flow $-216.16MM $89.94MM $-105.78MM
Financing Cash Flow $272.37MM $4.08MM $218.46MM
Earnings Per Share* $-1.64 $-2.62 $-2.92

* EPS are Split Adjusted, recent splits may be reflected with a delay.